- $138.91m
- $112.99m
- $44.86m
- 41
- 19
- 53
- 31
Annual cashflow statement for Augmedix, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -18.5 | -15.6 | -17.9 | -24.4 | -19.2 |
| Depreciation | |||||
| Non-Cash Items | 1.67 | 1.36 | 0.566 | 4.61 | 4.46 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 1.23 | -1.02 | -2 | 2.21 | -1.82 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Net Change in Other Assets & Liabilities | |||||
| Cash from Operating Activities | -14.6 | -14.4 | -18.6 | -16.8 | -15.4 |
| Capital Expenditures | -0.823 | -0.647 | -0.611 | -1.41 | -3.1 |
| Purchase of Fixed Assets | |||||
| Cash from Investing Activities | -0.823 | -0.647 | -0.611 | -1.41 | -3.1 |
| Financing Cash Flow Items | -0.053 | -3.76 | -4.36 | -0.142 | -0.72 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 17.2 | 26.4 | 37.8 | -1.24 | 43.4 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 1.69 | 11.4 | 18.6 | -19.6 | 24.4 |